An observational study in Cardiac Arrhythmia, sponsored by Biotronik SE & Co. KG. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Biotronik SE & Co. KG · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Arrhythmias, Cardiac by Biotronik SE & Co. KG — 3 open to participants now, 4 under way, none of them phase 3. Arrhythmias, Cardiac · Biotronik SE & Co. KG.
Among the 12 studies in Arrhythmias, Cardiac by Biotronik SE & Co. KG, this one is the only one that started in 2023, is one of 3 observational ones, and was the 9th registered.
1,052 studies on the registry are indexed under Arrhythmias, Cardiac; 236 are open to participants now.
Browse Arrhythmias, Cardiac studies →3 of the 12 studies in Arrhythmias, Cardiac by Biotronik SE & Co. KG are open now, in 8 countries. Recruiting first, the newest first:
Biotronik, Inc. · Sites in United States, Australia, Austria and 5 more countries
Ages 18+
Biotronik SE & Co. KG · Sites in Belgium, Germany
Ages 18+
By country, each count listing its studies:
Of the 167 Arrhythmias, Cardiac studies recruiting now, 119 (71%) set no upper age limit and 13 (8%) stop at 75 or younger; 31 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 280 is above the median of 200 across 467 observational studies indexed under Arrhythmias, Cardiac.
Median enrollment 198 across the 9 interventional studies, 88 across the 3 observational. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
Biotronik SE & Co. KG is the lead sponsor of 83 studies on the registry; 6 are open to participants now.
1 of the studies in Arrhythmias, Cardiac by Biotronik SE & Co. KG that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07118358Biotronik, Inc.BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Arrhythmias, Cardiac by Biotronik SE & Co. KG, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This data collection is designed to provide evidence for the safety, performance, and clinical benefit of BIOTRONIK's EP products. Additionally, residual risks will be monitored and newly emerging risks identified.
In this study, data from routine care will be collected and evaluated to support regulatory post-market clinical follow-up demands under MDR as well as maintenance of the regulatory approval of the BIOTRONIK's EP product portfolio in the CE region. This is a prospective, observational, multi-center, international, open-label, non-randomized study that aims to provide evidence for the clinical safety, performance, and clinical benefit of BIOTRONIK's EP products. The patients participating in the study either receive a diagnostic or therapeutic catheter intervention, which are indicated for temporary transvenous application in patients with cardiac arrhythmias. They will be used in combination with external devices like RF generators, external pacemakers cardiac stimulators and / or irrigation pumps.
Patients indicated for diagnosis and treatment of intracardiac arrhythmias in an EP lab environment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
EP intervention is planned to involve the use of BIOTRONIK EP products from at least 2 of the 3 following categories:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ablations and diagnostic catheters are indicated for temporary transvenous application in patients with cardiac arrhythmias during electrophysiology study (EPS) or catheter ablation interventions. They will be used in combination with external devices like RF generators, external pacemakers cardiac stimulators and / or irrigation pumps.
Rate of Device deficiencies
Device deficiencies for each investigational device type that occur during the EP procedures in patients, users or other persons
Time frame: During EP procedure
Rate of Peri-procedural adverse device effects for each investigational device type
Peri-procedural adverse device effects for each investigational device type that occur in all patients until or at the 24-hour follow-up
Time frame: Until or at 24-hour follow-up
Rate of Post-procedural adverse device effects
Post-procedural adverse device effects that occur in the AlCath group after the 24-hour follow-up until or at the 3- to 6-month follow-up
Time frame: After the 24-hour follow-up until or at the 3- to 6-month follow-up
Percentage of Clinical benefit confirmations per number of use cases
Clinical benefit at the time of procedure for each investigational device type
Time frame: At the time of procedure
Procedure setting (related to used BIOTRONIK EP products and competitor products)
Type of procedure, type of catheter models, recording system, RF ablation generator, irrigation pump, stimulator, 3D system, patient cable
Time frame: Intervention
Procedural parameters
Fluoroscopy time, Procedure duration, duration of RF energy delivery, date and time of procedure
Time frame: Intervention
Patient details
demographics, medical history, and concomitant cardiovascular medication
Time frame: Baseline
Device performance
e.g., successful insertion and advancing of catheter, successful stimulation and recording of intracardiac signals, RF energy application, removal, replacement/substitution of catheter, device used within its intended purpose
Time frame: Intervention
Plan to share: Yes — Upon resonable request by authors or other scientifc reasons, but requires explicit approval by the sponsor.
Supporting information: Study protocol, Statistical analysis plan
Time frame: The data will become available with uploading the results to clinical trial.gov. The data will be available as long as the study documents are archived.
Access criteria: On demand; in case of request by an author or in case of scientific reasons, but requires explicit approval by the sponsor.
No publications or documents are linked to this record.
Started Jan 2023 (actual). Primary completion is estimated for Jul 2030, 90 months after the start.
Of 69 industry-sponsored observational studies under Arrhythmias, Cardiac, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 51. This study's planned 90 months is above that.
Counting every sponsor, half of 259 studies reached it within 38 months; a quarter within 16 and three quarters within 97.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.